GlassScriptPhysician profile
Jian Kang
NPI 1114112026
$3,363.87
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $177 · 2021: $763 · 2022: $860 · 2023: $921 · 2024: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189 · Honoraria: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.85 |
| Honoraria | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $724.59 | 2021-2023 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $544.01 | 2021-2024 | Dupixent |
| Abbvie INC. | $484.05 | 2019-2023 | |
| Genzyme Corporation | $192.49 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $190.62 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $175.00 | 2024 | |
| Glaxosmithkline, LLC. | $169.09 | 2021-2023 | Nucala |
| Kaleo, INC. | $103.52 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.08 | 2021-2024 | Hyqvia |
| Optinose US, INC. | $81.76 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $80.66 | 2023-2024 | |
| Csl Behring | $80.23 | 2021-2024 | Haegarda |
| Pharming Healthcare, INC. | $68.37 | 2023 | Ruconest |
| Genentech USA, INC. | $62.21 | 2021-2022 | |
| Incyte Corporation | $52.09 | 2023-2024 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $50.32 | 2023 | Ayvakit |
| Mylan Specialty L.P. | $44.35 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $34.13 | 2022 | |
| Novo Nordisk INC | $31.87 | 2019 | |
| Sanofi Pasteur INC. | $31.75 | 2019-2020 | |
| Amgen INC. | $30.77 | 2023-2024 | Tezspire |
| Merck Sharp & Dohme LLC | $14.06 | 2021 | |
| Uswm, LLC | $14.04 | 2021 | |
| Amarin Pharma, INC. | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jian Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.